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The integrin avb6 is up-regulated in several cancers and has clinical potential for both tumour
imaging and therapy. Peptide ligands have been developed which show good binding specificity
for avb6 and provide an opportunity to study the interaction in more detail by NMR. Such
studies ideally require 15N and 13C labelled peptides, and recombinant expression within E. coli
provides a cost effective way of generating isotopically labelled proteins and peptides. In this
study we have used an insoluble fusion partner (ketosteroid isomerase) to produce high yields of
recombinant peptide. The insoluble nature of the fusion allowed simple product recovery by cell
lysis and centrifugation, and thorough washing of the insoluble pellet to remove contaminating
proteins avoided the need for nickel-affinity chromatography in denaturing conditions which is
the standard procedure. The protocol described here is convenient to scale-up and requires only
one chromatography step (reverse-phase HPLC) which is comparable to solid-phase synthesis.
Introduction
The epithelial-specific integrin avb6 is expressed at low or
undetectable amounts in normal human adult tissue but
up-regulated during tissue remodelling processes, e.g. wound
healing, development and inflammation,1 and in more severe
pathologies such as chronic skin wounds2 and cancer.3 avb6
binds with high-affinity to protein ligands containing an RGD
(Arg-Gly-Asp) motif. Known naturally occurring ligands
include fibronectin, tenascin, the latency associated peptides
(LAP) of TGFb14 and TGFb3,5 and the VP1 coat protein of
foot-and-mouth disease virus (FMDV).6 The amino acid
consensus sequence RGDLxxL/I has been shown to be a key
determinant of the binding specificity of avb67 and experi-
ments with a 15-mer peptide containing this motif were shown
to prevent infection of baby hamster cells by FMDV.8
Peptide antagonists for avb6 have the potential for clinical
use in both the treatment and imaging of several cancers
including pancreatic and colon cancer. Structural analysis of
20-mer peptides from the VP1 coat protein of FMDV and the
latency associated peptide of TGFb1 revealed that secondary
structure is also important for binding potency, in particular,
an a-helix immediately proximal to the RGD hairpin that
brings the two Leu residues in the consensus sequence together
on the same face of the helix.9 The potency of different
peptides was also found to be related to the length and
propensity of helix formation, and furthermore, NMR experi-
ments revealed that the two Leu residues are in close contact
with the integrin when the peptide is bound which suggests
that the helix is present in the bound conformation of the
peptide.9
To enable further NMR-based studies into the structure,
dynamics and binding interactions of peptide ligands for avb6,
it was desirable to generate 15N and 13C isotopically labelled
peptides. Such an approach allows the use of more
sophisticated multi-dimensional NMR and nucleus-selective
editing techniques to provide more detailed information than
possible with homonuclear 1H NMR alone.10
The production of peptides for NMR analysis has typically
been carried out by solid-phase synthesis. This method is
convenient and relatively inexpensive, but costs increase
significantly for isotopically labelled peptides (2H, 13C, 15N).
A cheaper alternative is to use recombinant expression in
E. coli. This method allows large quantities of peptide to be
generated with higher fidelity than chemical synthesis, and
the host can be grown on relatively inexpensive media
containing 2H, 13C and 15N as sole hydrogen, carbon and
nitrogen sources.
Several expression systems have been tried for the recombi-
nant production of peptides in E. coli. Early work revealed
that peptides need to be expressed with a fusion partner or in
tandem constructs to protect the product from intracellular
degradation.11 Several fusion systems are commercially
available, the most popular being fusions with maltose binding
protein, glutathione S-transferase, small ubiquitin-like
modifier and thioredoxin. These fusion partners are highly
expressed, soluble and provide a convenient method of affinity
purification. The highest peptide yields have been obtained
from those fusion partners with the lowest molecular weight,
and good results have been obtained from the B1 domain of
protein G which is only 6 kDa in size (12–50 mg l1 purified
peptide12). Peptides can be cleaved from the soluble fusion
using restriction proteinases, e.g. thrombin, enterokinase or
factor Xa.
An alternative to using a system that generates a soluble
fusion protein on intracellular expression in E. coli is to use a
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fusion partner that is highly insoluble. Such a system has a
number of benefits. Insoluble proteins often have the highest
expression yields,13,14 and as the recombinant product
is sequestered into inclusion bodies, the peptide is further
protected from degradation. The formation of inclusion
bodies allows the recombinant product to be recovered
easily by simple cell lysis followed by centrifugation. The
sequestration also allows the expression of toxic peptides at
high level.15,16 Several systems have been described,17–21 of
which one (ketosteroid isomerase; 125 residues) is commer-
cially available (pET31b, Novagen).
In this study, four 20-mer peptide ligands for avb6 were
expressed as C-terminal fusions with ketosteroid isomerase
(KSI) in E. coli.17 The pET31b vector allows the insertion of
tandem copies of the DNA peptide-coding sequence to
increase final peptide yield, and constructs with 1, 2 or 3
peptide repeats were characterised. The vector codes for a
C-terminal His6-tag to allow nickel-affinity purification of the
fusion protein in denaturing conditions. The peptides are then
released from the fusion partner, His6 tag and each other by
cyanogen bromide (CNBr) cleavage at methionine residues
that separate each peptide sequence. In this work we have
shown that the standard nickel-affinity purification step in
denaturing conditions used by the majority of workers can be
replaced by an inclusion body washing procedure to remove
contaminating E. coli proteins that is both more convenient
and less costly. Final peptide yields of between 5 and 15 mg l1
of culture were obtained from minimal media with 15N and/or
13C incorporation.
Materials and methods
Design and construction of expression vector
HPLC purified coding and non-coding DNA sequences for
four 20-mer RGD-containing peptides were purchased from
MWG (London, UK) with 50 phosphate groups. The
sequences were optimised for E. coli codon usage and designed
to give ATG overhangs at both 30 ends when annealed
(the ATG nucleotides code for the Met residues between each
peptide). The amino acid sequences of the 4 peptides were:
A20fmdv2 (NAVPNLRGDLQVLAQKVART), A20lap2
(GFTTGRRGDLATIHGLNRPF), DBD1 (EKCPNLRGD-
LQVLAQKVCRT) and TGFb3 (NEDDHQRGDLGRLKK-
QKDHH).
The coding and non coding oligonucleotides (1.0 pmol ml1)
for each peptide were annealed by heating to 100 1C or 121 1C
in TES buffer (20 mM Tris-HCl, 2 mM EDTA, 100 mMNaCl,
pH 8.0) for 5 min in an insulated water bath or bench
autoclave before allowing to cool slowly over several hours
to room temperature. Samples of the annealed DNA were
ligated with pET31b(+) previously cleaved with the
restriction enzyme AlwNI to generate compatible ends and
then dephosphorylated. E. coli (DH5a) were transformed with
the ligated DNA and ampicillin-resistant colonies screened for
the correct incorporation of one or more DNA inserts by
DNA restriction analysis (using XhoI and Xbal enzymes), PCR
(using primers that anneal at the T7 terminator sequence
(GCTAGTTATTGCTCAGCGG) and within the KSI coding
sequence (GGCAAGGTGGTGAGCATC)) and DNA
sequencing of the inserted region (Lark Technologies, UK).
Protein expression
E. coli (strain BL21 (DE3); Novagen) were transformed with
pET31b containing 1, 2 or 3 peptide repeats and grown at
37 1C in Luria Bertani (LB) medium or M9 minimal medium
containing 15N ammonium sulphate (0.6 g l1) or 13C glucose
(2 g l1) as sole nitrogen or carbon sources. Cultures were
grown at 37 1C with shaking at 200 rpm until the cell density as
measured by absorbance at 600 nm reached 0.6. At this point,
IPTG (1.0 mM) was added to induce recombinant protein
expression and the culture incubated under the same
conditions for a further 3 h.
Inclusion body isolation and washing
After the induction period (final A600 = 1.2–1.4), E. coli were
harvested from 400 ml cultures by centrifugation (6000g,
15 min, 4 1C) and resuspended in 10 ml of lysis buffer
(50 mM Tris-HCl, 2 mM EDTA, pH 8). Cells were lysed
by the addition of lysozyme (0.1 mg ml1) and Triton X-100
(0.1% v/v) as previously described.22,23 The genomic DNA
released on cell lysis was removed by incubation with DNase I
(0.02 mg ml1) and MgCl2 (10 mM) for 20 min at room
temperature. To ensure complete cell breakage, lysis mixtures
were also cooled on ice and ultrasonicated for 2 min with
alternate 10 s pulse and wait periods.
Insoluble protein was collected by centrifugation (12 000g,
10 min at 4 1C) and resuspended in 2.5 ml of wash buffer
(50 mM Tris-HCl, 10 mM EDTA, 0.5% (w/v) Triton X-100,
pH 8.0). The suspension was transferred to a hand-held
ground-glass homogenizer to allow maximal disaggregation
of the inclusion body pellet. The inclusion bodies were
recovered from the wash buffer by centrifugation (12 000g,
10 min at 4 1C) and the washing step repeated. The procedure
was finally repeated twice with water to remove detergent from
the final preparation.
Cyanogen bromide cleavage and peptide recovery
Washed inclusion bodies were dissolved in 5 ml of formic acid
(80% (v/v)) to which CNBr (0.2 g) was added and the mixture
incubated for 18–24 h at room temperature in the dark.
Non-volatile material was recovered from the digest by
lyophilization after first diluting the mixture 5-fold with water.
This material was then resuspended in 2.5 ml of 50 mM
sodium phosphate buffer containing 100 mM NaCl and the
pH adjusted to 7.5–8.0 by the addition of NaOH. The
suspension was stirred for 16 h at room temperature in
the dark to allow solubilisation of the released peptides. The
soluble fraction was collected by centrifugation.
Modifications to the procedure were made for the A20lap2
and DBD1 peptides. CNBr cleavage of A20lap2 was carried
out in 80% (v/v) trifluoroacetic acid (TFA) as an alternative to
formic acid24 to avoid formylation of Thr residues in the
sequence. The DBD1 peptide was designed to be crossed-
linked by an intramolecular disulfide bond and solubilisation
of this peptide was carried out in 50 mM Tris-HCl, 100 mM
NaCl (pH 8.0) containing dithiothreitol (DTT) at a 2-fold
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molar excess over peptide concentration to ensure the cysteine
residues remained reduced during the solubilisation period.
After separation of the KSI carrier by centrifugation, the
DBD1 peptide was oxidized by the addition of a 4-fold molar
excess of oxidized glutathione before purification by reverse-
phase HPLC.
Reverse-phase HPLC purification
Resolubilised peptides were purified to homogeneity by HPLC
on a preparative C18 reverse-phase column (5 mm  150 mm,
Vidac) at room temperature. Peptides were eluted with a linear
gradient of acetonitrile (containing 0.045% TFA) in water
(containing 0.05% TFA). Absorbance was measured at
220 nm and peptide fractions were collected manually to
minimize cross-contamination. Peptides were recovered
from the HPLC fractions by lyophilisation and their masses
determined by electrospray mass spectrometry.
Peptide yield quantification
Estimates for peptide yield were made by comparison of peak
areas seen on reverse-phase HPLC with known amounts of an
A20fmdv2 peptide standard. The standard peptide was
produced recombinantly as a KSI-fusion and purified by
reverse-phase HPLC as described above. The concentration
of the standard was determined by amino acid analysis
(Alta Biosciences, Birmingham, UK).
Nuclear magnetic resonance (NMR)
15N/1H HSQC spectra were acquired on 1.0 mM peptide
samples in 20 mM sodium phosphate buffer (pH 6.5) containing
100 mM NaCl and 10% (w/v) 2H2O at 10 1C. Spectra were
collected on a 600 MHz Varian UnityINOVA spectrometer
equipped with a 5 mm HCN z-pulse field gradient probe as
previously described.25 Solvent-suppression to reduce the
water signal was carried out by the WATERGATE method.26
Data was processed using NMRPipe27 and analysed using the
CCPN Analysis package.28
Results and discussion
Ligation of the AlwNI cut pET31b vector with the annealed
double-stranded DNA coding for the 20-mer peptides
typically produced constructs with 1, 2 or 3 tandem inserted
sequences as determined by DNA restriction analysis and
PCR. The likelihood of a particular colony containing a
construct with 1, 2 or 3 inserts was found to be 53%, 17%
and 4%, respectively. DNA sequencing revealed high error
rates within the annealed region of the DNA inserts, requiring
constructs from up to 3 separate clones to be sequenced to
ensure that a correct coding sequence was found. Error rates
were generally lower when peptides were annealed by slow
cooling from 121 1C, rather than 100 1C as initially used. Small
scale preliminary work (data not shown) with peptide
A20fmdv2 revealed that final peptide yields were highest from
constructs containing 2 tandem repeats, and hence two-repeat
constructs were selected for all further production work. This
finding is consistent with other published work using peptides
of similar length.12,29,30
Constructs of interest were expressed in E. coli strain BL21
(DE3) grown in LB medium for unlabelled peptides, or
minimal medium containing 15N ammonium sulphate and/or
13C glucose as sole nitrogen and carbon sources for isotopi-
cally labelled peptides. The KSI–peptide fusion was found to
be entirely insoluble as expected (Fig. 1). Insoluble proteins
sequestered into inclusion bodies are conveniently purified
from the majority of host cell proteins by simple cell lysis
and centrifugation. Such methods typically give purities of
30–50%. However, further purification can be easily achieved
by washing the inclusion bodies in detergent or low concen-
trations of denaturants. Washing KSI–peptide fusions in 0.1%
Triton X-100 and EDTA gave inclusion body preparations
that were typically >70% recombinant product (Fig. 1). This
simple washing step avoided the need for more costly nickel
affinity chromatography in denaturing conditions which is the
standard and often-used purification approach. Fig. 1 shows
SDS-PAGE analysis of samples taken from the various stages
of cell lysis and inclusion body washing for KSI-A20fmdv2.
Washed inclusion bodies were solubilised directly in 80%
formic acid to allow cleavage with CNBr to release the
peptides from the KSI carrier and the C-terminal His6 tag.
Efficient cleavage was confirmed by SDS-PAGE analysis of
samples taken after CNBr treatment and lyophilisation
(Fig. 2). Peptides were recovered by resolubilisation of the
lyophilised material in phosphate buffer and then purified to
homogeneity by preparative reverse-phase HPLC. A typical
reverse-phase HPLC chromatogram is shown in Fig. 3.
Chemical cleavage by CNBr generates peptides with an
authentic N-terminus, but the methionine residue at the
C-terminus of the peptide where cleavage occurs is converted
Fig. 1 Expression and purification of a KSI fusion containing two
sequence repeats for the peptide A20fmdv2 analysed by SDS-PAGE.
Lane 1, molecular weight marker proteins (kDa); lane 2, total E. coli
proteins after IPTG induction of KSI-A20fmdv2 expression; lane 3,
insoluble protein fraction separated by centrifugation after cell lysis;
lane 4, soluble protein fraction after cell lysis; lanes 5 and 6, wash
supernatants collected from washing the insoluble fraction (inclusion
bodies) with Triton X-100/EDTA; lane 7, wash supernatant with
water; lane 8, washed inclusion bodies. Significant purification of the
recombinant product (indicated by arrow) was achieved by inclusion
body washing. The purity of the recombinant product in lane 8 was
estimated by gel densitometry to be >85%.
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into a mixture of products (homoserine and homoserine lactone).
These products can be resolved by reverse-phase HPLC
(Fig. 3), or the mixture converted to a single product either
by hydrolysis of the lactone to homoserine by treatment with
NaOH, or lactonisation of the homoserine to the lactone by
treatment with TFA.15,31 The proportion of homoserine to
homoserine lactone was found to be variable, but typically a
1 : 1 ratio was seen. Although not utilised in this work, the
lactone provides a convenient attachment point for specific
modification using amine-derivatives of reagents such as biotin
or fluorescein.15,17
Chemical cleavage with cyanogen bromide is inexpensive
and highly efficient, but the approach prevents the use of
methionine residues within the peptide sequence. Isoleucine is
often chosen as a conservative replacement for methionine,
but if methionine is an absolute requirement, then cysteine or
tryptophan could be considered as alternative residues for
which specific chemical cleavage protocols are available.17,29
The specificity of the AlwN1 restriction enzyme used for
cloning in the pET31b vector allows it to be engineered to
accept any 3-base 30 overhang on the insert DNA and hence
the opportunity to change the residue at the cleavage site.
Expression and purification yields for the four avb6-binding
peptides produced as KSI-fusions are shown in Table 1.
Expression yields were typically in excess of 80 mg l1 in LB
medium and 60 mg l1 in minimal medium, whilst purified
peptide yields averaged 18 mg l1 from LB medium and
9 mg l1 from minimal medium. These results are comparable
with other data reported in the literature15,17,29,32,33 and higher
than those typically seen with some commonly used soluble
fusion partners (e.g. glutathione S-transferase34). Indeed, we
have previously attempted to express 15N-labelled A20lap
(a peptide sequence identical to A20lap2 except for a Met to
Leu change) as a fusion with glutathione S-transferase and
only achieved yields of 0.23 mg l1 (unpublished data). Peptide
recovery expressed as a percentage of the theoretical maximum
(Table 1) was variable between different experiments and
preparations, although SDS-PAGE analysis revealed that
peptide cleavage from the carrier protein was essentially
complete in all cases (Fig. 2). Significant error in estimating
these values is likely to come from the determination of fusion
protein expression yield. Due to the insoluble nature of
this material, quantities were estimated by comparison of
Fig. 2 SDS-PAGE analysis of the remaining insoluble fraction of
KSI-A20fmdv2 with different numbers of peptide repeats after CNBr
cleavage, lyophilisation and peptide extraction. Lanes 1, molecular
weight marker proteins (kDa); lanes 2 and 3, KSI-A20fmdv2 with 1
repeat; lane 4, KSI-A20fmdv2 with 2 repeat; lanes 5 and 6,
KSI-A20fmdv2 with 3 repeat. The size of the major protein band
(shown by unbroken arrow) is consistent with KSI only hence showing
the high efficiency of the CNBr cleavage. The expected migration
positions of the different tandem repeat species if chemical cleavage
had not taken place are indicated by the broken arrows.
Fig. 3 Reverse-phase HPLC analysis of the A20fmdv2 peptide
(NAVPNLRGDLQVLAQKVART) solubilised from the KSI-fusion
after CNBr-cleavage and lyophilisation. HS denotes the homoserine
derivative, HSL the homoserine lactone. The C-terminal His6-peptide
(LLEHHHHHH) is also released from the insoluble KSI carrier.









Yield of KSI fusiona/mg l1 Yield of pure peptideb,c/mg l1
LB medium Minimal medium LB medium Minimal medium
A20fmdv2 1 155 13.4 160 — 16 (75) —
2 176 23.7 180 130 19 (45) 7.0 (23)
A20lap2 2 176 23.9 86 70 30 (146)e 15 (90)
DBD1d 2 176 24.5 80 65 7.4 (38) 5.3 (33)
TGFb3 2 176 25.7 — 70 — 10 (56)
a Yields estimated by comparison of coomassie-blue stained protein bands on SDS-PAGE to known standards. b Peptide concentrations
determined by peak area on reverse-phase HPLC compared to a standard (A20fmdv2) accurately quantified by amino acid analysis. Yields
include both the homoserine and homoserine lactone derivative and are for the peptide after preparative reverse-phase HPLC. c Values in
parentheses are % theoretical maximum yield. d CNBr cleavage carried out in 80% TFA to avoid formylation of Thr residues within the
sequence. e Value of % theoretical maximum yield higher than expected due to suspected error in estimating fusion protein yield where uniform
sampling of suspended inclusion preparations is required.
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band-staining intensities on SDS-PAGE to known amounts
of a standard. Accurate sampling of an inclusion body
suspension can be difficult, and band staining comparisons
are also prone to error. Peptide recoveries were not on average
different to those reported by others,32 and recoveries could be
improved slightly (5–10%) by repeat buffer extractions.
Mass spectrometry analysis of the purified peptides
confirmed their authenticity (all experimentally determined
masses were within 0.5 Da of the expected mass) and
incorporation of 15N and 13C nuclei was typically >98%.
NMR analysis also confirmed the chemical authenticity of the
peptides, and in the case of A20fmdv2, allowed direct
Fig. 4 15N/1H HSQC spectra of (a) chemically synthesized A20fmdv2 (data collected from naturally abundant 15N isotope (0.37%)),
(b) recombinant 15N-labelled A20fmdv2, (c) recombinant 15N-labelled A20fmdv2 in the presence of 30% (v/v) trifluoroethanol, and
(d) recombinant 15N-labelled DBD1. Peaks are labelled in each spectrum with the residue number and residue type; labels in regular text are
backbone NH resonances, those in italics and underlined are for NH or NH2 groups in sidechains. Assignments were made from recombinant
peptide using standard 15N-edited NOESY and TOCSY experiments. The recombinant samples were enriched in the homoserine lactone derivative
(Hsl) by separation on reverse-phase HPLC, although a small amount of the homoserine derivative was also present (Hse). The chemical shift of
the penultimate amino acid in A20fmdv2 (b and c) is also affected by the nature of the homoserine derivative and these two species are labeled
20Thr (Hse) and 20Thr (Hsl).
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comparison with chemically synthesised material (Fig. 4a and b).
The 15N/1H HSQC spectra shown in Fig. 4 show a signal for
each backbone amide group (NH), and a pair of peaks for each
sidechain NH2 group (Asn and Gln). The recombinant
material includes an additional C-terminal homoserine or homo-
serine lactone residue. The presence of the homoserine residue
changes the environment of the preceding residues; hence the
peak for the backbone NH of Thr20 is shifted from 121 to
116 ppm in the 15N dimension, and a chemical shift change is
also seen for Arg19, but to a much smaller extent. If the presence
of a C-terminal homoserine or homoserine lactone residue is
undesirable, then a stop codon can be added immediately at the
end of the peptide. This approach would prevent the use of
tandem constructs, but good yields of recombinant peptide are
still obtained even with a single unit (see Table 1). This method
would also avoid the production of the His6 tag peptide from
which the target peptide must be purified.
The A20fmdv2 peptide has been shown to be essentially
unstructured in aqueous solution at pH 6.5.9 This finding is
consistent with the 1H chemical shifts seen for the backbone
NH groups (Fig. 4b) that all fall between 8.1 and 8.6 ppm and
are typical for a random coil conformation.35 The addition of
the structure-enhancing co-solvent trifluoroethanol (TFE) to
A20fmdv2 (Fig. 4c) caused increased dispersion of the signals
in the 1H dimension suggesting the formation of secondary
structure. NMR distance constraints (NOEs) collected in the
presence of TFE revealed a backbone helical conformation
immediately proximal to the RGD motif (residues Leu10 to
Val17), whereas these NOE signals were absent from NOESY
spectra collected in the absence of TFE.9 The peptide DBD1
(Fig. 4d) was designed as a variant of the A20fmdv2 sequence
with an intramolecular disulphide bond between the N- and
C-terminal regions to constrain the peptide into a ‘‘loop’’-like
structure. This arrangement stabilises the formation of the
helix after the RGD motif in aqueous conditions which is
observed in the 15N/1H HSQC spectrum by increased 1H
resonance dispersion (Fig. 4d) and confirmed by further
NMR structural analysis (unpublished data).
In summary, the KSI fusion approach provides an efficient
method of generating recombinant peptides. The method
described here avoids the need for nickel affinity purification
in denaturing conditions and employs a single column
purification step (preparative reverse-phase HPLC) no
different than would be routinely used after solid-phase
peptide synthesis. Final yields are high and typically several
fold greater than could be obtained from other recombinant
methods. Importantly, the protocol allows simple scale-up and
is particularly useful for generating isotopically labelled
peptides for biological NMR studies. The use of an insoluble
fusion partner for recombinant peptide production has not
been as widely adopted as we feel it deserves.
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